Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice

2019 ◽  
Author(s):  
Keyword(s):  
Clinical Practice ◽  
Health Professionals ◽  
Allergen Immunotherapy ◽  
Selection Of ◽  
Real Clinical Practice

scholarly journals Pro- and synbiotics in the treatment of intestinal diseases: what effects can we expect?

2020 ◽  
Vol 22 (12) ◽  
pp. 37-43
Author(s):  
Olga V. Gaus ◽  
◽  
Maria A. Livzan ◽  
Keyword(s):  
Clinical Practice ◽  
Digestive Tract ◽  
Diagnostic Methods ◽  
Intestinal Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Relationship ◽  
Selection Of ◽  
Real Clinical Practice

The relationship between intestinal microbiota and human health is widely recognized. The advent of molecular and genetic diagnostic methods has made it po-ssible to make truly revolutionary discoveries in the field of understanding the role of the digestive tract microbiome. Many studies have proved the association of the composition of microbiota with the development of a number of diseases of the digestive tract, such as inflammatory bowel diseases, functional gastroin-testinal disorders and some types of cancer. The food and pharmaceutical industry has presented a huge selection of food products, dietary supplements and medicines containing prebiotic and probiotic components. The use of agents that affect microbiota in the treatment of intestinal diseases in real clinical practice should be carried out strictly in accordance with the indications, in recommended doses.

scholarly journals Selection of desmopressin preparations for the treatment of central diabetes insipidus

2017 ◽  
Vol 14 (4) ◽  
pp. 23-30
Author(s):  
Elena V. Biryukova
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Diabetes Insipidus ◽  
High Efficiency ◽  
Central Diabetes Insipidus ◽  
Severe Pathology ◽  
Central Form ◽  
Selection Of ◽  
Real Clinical Practice

Central diabetes insipidus (CDI) is a severe pathology of the hypothalamic-pituitary system, based on a deficit of antidiuretic hormone (ADH). The disease is a life threating condition for patients without adequate replacement therapy by various preparations of arginine vasopressin. This review presents the current concepts on etiology, pathogenesis, diagnostic proсedures, and treatment of CDI. The article gives comparative pharmacological characteristics of various desmopressin forms for the treatment of the central form of disease. When choosing a therapy for the treatment of CDI, the article highlights the long-term high efficiency and safety of the original sublingual form of desmopressin (Mininin Melt), which is confirmed by real clinical practice and clinical trials, including the comparison with other forms of desmopressin.

In real clinical practice osteoporosis drugs are taken for a very short period: analysis of persistence in the campania region

2013 ◽  
Author(s):  
Giovanni Iolascon ◽  
Annarita Capaldo ◽  
Valentina Orlando ◽  
Enrica Menditto ◽  
Francesca Gimigliano
Keyword(s):  
Clinical Practice ◽  
Campania Region ◽  
Period Analysis ◽  
Short Period ◽  
Real Clinical Practice

PCSK9 inhibitors as an add on for the treatment of dislipemia in real clinical practice

2018 ◽  
Author(s):  
Carmen Hernandez Garcia ◽  
Cristina Maria Diaz Perdigones ◽  
Miguel Damas Fuentes ◽  
Clara Estaun Martinez ◽  
Andrea Sanchez Ramos ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Pcsk9 Inhibitors ◽  
Real Clinical Practice

Comprehensive assessment of drug consumption as a basis for pharmacotherapy optimization

2019 ◽  
pp. 22-31
Author(s):  
Olga Vyacheslavovna Zhukova
Keyword(s):  
Clinical Practice ◽  
Treatment Options ◽  
Comprehensive Assessment ◽  
Drug Consumption ◽  
Treatment Standards ◽  
Disease Epidemiology ◽  
Efficacy Analysis ◽  
Epidemiological Monitoring ◽  
Guidelines Development ◽  
Real Clinical Practice

This article describes the rationale for methodology of comprehensive assessment of drug consumption in real clinical practice. The proposed methodology includes three stages: 1) epidemiological monitoring – disease epidemiology assessment; assessment of the role of factors leading to the disease; 2) pharmacoepidemiological monitoring – assessment of pharmacotherapy in real clinical practice; clinical efficacy analysis of drugs; cost-effectiveness analysis; 3) long-term clinical and economical evaluation of various treatment options. Comprehensive assessment of drug consumption should result in optimal pharmacotherapy regimens, decrease of the drug load, increasing of the therapy effectiveness and cost reduction. The scheme of comprehensive assessment of drug consumption is universal and can be used for clinical guidelines development, treatment standards, for the optimal formation of drugs lists at the federal level. Separate stages and sub-steps of an integrated assessment also can be used at the territorial and local levels, medical institution, to optimize pharmacotherapy.

Pharmacoepidemiological Analysis of Pharmacotherapy for Burn Injuries in Real Clinical Practice

2020 ◽  
pp. 70-79
Author(s):  
Olga Vyacheslavovna Zhukova ◽  
Ekaterina Sergeevna Nekaeva ◽  
Elena Sergeevna Khoroshavina ◽  
Ekaterina Alexeevna Kozlova ◽  
Yulia Alexandrovna Dudukina ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Average Cost ◽  
Burn Injury ◽  
General Structure ◽  
Burn Injuries ◽  
Antimicrobial Drugs ◽  
Positive Tendency ◽  
Defined Daily Doses ◽  
Duration Of Hospitalization ◽  
Real Clinical Practice

Objective: to conduct pharmacoepidemiological analysis and analysis of the costs of pharmacotherapy, taking into account the actual consumption of drugs in the real inpatient clinical practice at the federal center in Russia. Materials and methods. Data from the medical records of 14 patients with burn injury, who were hospitalized in 2018, was analyzed. Patients’ age was from 23 to 67 years (44,93 ± 14,66). Duration of hospitalization was from 17 to 62 days (35,93 ± 14,17). We calculated rate of prescription foe each drug and its share in general structure of all utilized drug courses (n = 460). We performed frequency analysis of prescription structure, DDD (defined daily doses) analysis, DU90% (Drug Utilization 90%) analysis, ABC-analysis and analysis of average cost of pharmacotherapy. Results. Most frequently used drugs, prescribed in 75-100% of all hospital cases, included 15 names, e.g. 2 antimicrobial drugs (vancomycin and amikacin), 19 were used commonly, including 4 antimicrobial drugs (co-trimoxazole, cefoperazone/sulbactam, tigecyclin and cefepime). Other drugs were used in less than 25% of cases. 33 drugs made 90% of all consumed NDDD, including 5 antimicrobial drugs (vancomycin, amikacin, co-trimoxazole, cefoperazone/sulbactam and tigecyclin). These drugs comprised 70,24% in the prescription structure. The cost of one DDD in DU90% segments (512,33 rubles) is 1,4 higher than in DU10% segment (649,34 rubles). Average cost of drugs included in DU90% group was 4735,89 rubles vs 4966,80 rubles for drugs from DU10% group. This finding shows positive tendency of burn injuries pharmacological treatment. Conclusion. We obtained the data, which can be used for comparison of real clinical practice costs with a current payment rates for medical care.

scholarly journals Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

2021 ◽  
pp. jim-2020-001633
Author(s):  
Florentino Carral San Laureano ◽  
Mariana Tomé Fernández-Ladreda ◽  
Ana Isabel Jiménez Millán ◽  
Concepción García Calzado ◽  
María del Carmen Ayala Ortega
Keyword(s):  
Type 1 Diabetes ◽  
Clinical Practice ◽  
Retrospective Study ◽  
Real World ◽  
Glycosylated Hemoglobin ◽  
Routine Clinical Practice ◽  
Insulin Analogs ◽  
Total P ◽  
Real Clinical Practice

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p<0.001) than patients using IDeg (n=225). Total (0.77±0.36 unit/kg/day), basal (0.43±0.20 unit/kg/day) and prandial (0.33±0.23 unit/kg/day) DIDR were similar in IGla-300 and IDeg groups. Patients with HbA1c ≤7% (n=113) used significantly lower basal (p=0.045) and total (p=0.024) DIDR, but not prandial insulin (p=0.241), than patients with HbA1c between 7.1% and 8% and >8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.

scholarly journals Biomarkers of Angiogenesis and Neuroplasticity as Promising Clinical Tools for Stroke Recovery Evaluation

2021 ◽  
Vol 22 (8) ◽  
pp. 3949
Author(s):  
Lidia Wlodarczyk ◽  
Rafal Szelenberger ◽  
Natalia Cichon ◽  
Joanna Saluk-Bijak ◽  
Michal Bijak ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Stroke Recovery ◽  
Clinical Scales ◽  
Recovery Processes ◽  
Recovery Potential ◽  
Current State ◽  
Standard Procedures ◽  
Key Issues ◽  
Clinical Tools ◽  
Selection Of

Several key issues impact the clinical practice of stroke rehabilitation including a patient’s medical history, stroke experience, the potential for recovery, and the selection of the most effective type of therapy. Until clinicians have answers to these concerns, the treatment and rehabilitation are rather intuitive, with standard procedures carried out based on subjective estimations using clinical scales. Therefore, there is a need to find biomarkers that could predict brain recovery potential in stroke patients. This review aims to present the current state-of-the-art stroke recovery biomarkers that could be used in clinical practice. The revision of biochemical biomarkers has been developed based on stroke recovery processes: angiogenesis and neuroplasticity. This paper provides an overview of the biomarkers that are considered to be ready-to-use in clinical practice and others, considered as future tools. Furthermore, this review shows the utility of biomarkers in the development of the concept of personalized medicine. Enhancing brain neuroplasticity and rehabilitation facilitation are crucial concerns not only after stroke, but in all central nervous system diseases.

Sign in / Sign up

Export Citation Format

Share Document